Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

The “perfect storm” for Fibromyalgia, CFS/ME, and fatigue in general is preparing to hit. A combination of poor nutrition, decreasing sleep, increasing stress and environmental toxins has created a human energy crisis of unprecedented proportions. Over the past 10 years, the incidence of Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS) has exploded by 400 to 1000 percent, as documented in five separate studies. The numbers for those with CFS in the U.S., previously estimated at 500,000, are now being re-tallied at closer to 1- 2.5 million. Previous estimates placed the number of Americans with FMS at 6 million. Studies worldwide suggest this has likely gone up in the last decade to ~ 12-24 million Americans! Meanwhile, ¼ of Americans suffer with chronic pain and most are fatigued.

28 Mar 2011

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started for the Phase 1 clinical trial testing the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes (study # MF101-008), also known as "menopausal hot flashes."

28 Mar 2011

Metagenics announces 2011 schedule for educational programs in lifestyle medicine

Metagenics Inc., a nutrigenomics and lifestyle medicine company dedicated to reducing chronic illness and improving health, announced today the 2011 schedule for educational programs in lifestyle medicine as well as for certification programs for its FirstLine Therapy, a turnkey, lifestyle medicine program.

28 Mar 2011

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

The U.S. Food and Drug Administration today approved Yervoy to treat patients with late-stage melanoma, the most dangerous type of skin cancer.

28 Mar 2011

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Pregnant women can benefit from low-to-moderate intensity weight-training program

Despite decades of doctors' reluctance to recommend weight training to pregnant women, a new University of Georgia study has found that a supervised, low-to-moderate intensity program is safe and beneficial.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

XTL announces MinoGuard acquisition

XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

HCG hormone therapy may benefit patients with intractable pain

Results from a small study of intractable pain patients being treated with the human chorionic gonadotropin (HCG) hormone reported that they had experienced pain free hours in the past month. These results were presented at a poster session at the American Academy of Pain Medicine's 27th Annual Meeting.

25 Mar 2011

Study demonstrates bisphenol A effect on animal embryonic development

Bisphenol A, whose impact on reproduction and development is the subject of numerous studies, induces anomalies in the inner ear of embryos of certain vertebrates.

25 Mar 2011

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Sanofi-aventis announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.

25 Mar 2011

Scientists discover hormone pathway that can lead to new diabetes treatment

Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.

25 Mar 2011

Sitagliptin drug can slow onset of diabetes

Diabetes type 2 is caused by insufficient levels of insulin to keep blood glucose under control. Excessive levels of another hormone, glucagon, can also contribute to diabetes type 2 by causing the liver to flood the body with stored glucose.

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Mother's gene variation can influence alcohol-related disorders in fetus

Exposure to alcohol in the womb doesn't affect all fetuses equally. Why does one woman who drinks alcohol during pregnancy give birth to a child with physical, behavioral or learning problems -- known as fetal alcohol spectrum disorder -- while another woman who also drinks has a child without these problems?

24 Mar 2011

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide have been accepted for presentation at the National Kidney Foundation 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.

24 Mar 2011

Researchers create new computational model to understand animal cell behavior

Biological systems, including cells, tissues and organs, can function properly only when their parts are working in harmony. These systems are often dauntingly complex: Inside a single cell, thousands of proteins interact with each other to determine how the cell will develop and respond to its environment.

24 Mar 2011

Research examines BNP’s role in predicting cardiac events after CABG surgery

More than 250,000 patients undergo coronary artery bypass graft surgery each year in the United States. New research in the April issue of Anesthesiology examines whether the hormone plasma B-type natriuretic peptide helps indicate which patients are at risk of adverse cardiac events after CABG surgery.

24 Mar 2011

Hormone News and Research

Further Reading

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Metagenics announces 2011 schedule for educational programs in lifestyle medicine

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Pregnant women can benefit from low-to-moderate intensity weight-training program

Study finds increased risk of VTE during first year of combination oral contraceptive usage

XTL announces MinoGuard acquisition

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

HCG hormone therapy may benefit patients with intractable pain

Study demonstrates bisphenol A effect on animal embryonic development

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Scientists discover hormone pathway that can lead to new diabetes treatment

Sitagliptin drug can slow onset of diabetes

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Mother's gene variation can influence alcohol-related disorders in fetus

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Researchers create new computational model to understand animal cell behavior

Research examines BNP’s role in predicting cardiac events after CABG surgery

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News